Warren, Wyden, and Sanders wrote to Kennedy that “the dinners may have served as an opportunity for Big Pharma to gain insider access to both you and President Trump” and asked the HHS chief to reveal ...

In a report released today, Charles Pitman CFA from Barclays reiterated a Buy rating on UCB SA (0NZT – Research Report), with a price target of €240.00. The company’s shares closed last ...

Innocan Pharma Ltd. Each Warrant is exercisable into one Common Share at a price of CAD$0.26 for a period of four (4) years from the date of issuance. Innocan intends to use the proceeds of the ...

HERZLIYA, Israel and CALGARY, AB, March 7, 2025 /CNW/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the "Company" or "Innocan") is pleased to announce that it has closed its ...

Pharmaceutical companies control and hide ... can take immediate action as part of his prioritization of “radical transparency” to aid his mission to “Make America Healthy Again.” ...

This lack of transparency grants drugmakers incredible power over the decisions of doctors, patients and even governments through controlling the information they see. From 1999 to 2014, ...

HERZLIYA, Israel and CALGARY, AB, Feb. 27, 2025 /PRNewswire/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the "Company" or "Innocan") is pleased ...

Berenberg raised the firm’s price target on UCB (UCBJF) to EUR 220 from EUR 130 and keeps a Buy rating on the shares. See what stocks are receiving Strong Buy ratings from top-rated analysts.